Gilead enters $5bn R&D deal with Galapagos
Gilead will pay more than $5 billion as part of a collaborative research and development agreement with Belgian-Dutch pharmaceutical company Galapagos.
Indivior appeal fails to stop generic opioid addiction challenge
The US Court of Appeals for the Federal Circuit has upheld an earlier ruling that Indivior cannot stop two competitors from making a generic version of one of its drugs.
German Court rules Sanofi’s Praluent infringes Amgen patent
A German court has found that Sanofi’s high-cholesterol treatment, Praluent, infringes one of Amgen’s patents.
Reckitt Benckiser to pay $1.4bn over opioid treatment sales
Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.
Number of patents invalidated by Alice drops by 23%
There has been a significant drop in the number of patents invalidated due to so-called Alice challenges since Federal Circuit rulings in Berkheimer v HP, and Aatrix Software v Green Shades Software, according to a new report.
Fed Circuit rejects Stanford DNA test appeal
The US Court of Appeals for the Federal Circuit yesterday, July 10, handed victory to researchers at the Chinese University of Hong Kong in a case involving a foetal testing patent.
Swiss court mulls extradition of Chinese researcher accused of GSK trade secrets theft
US authorities are seeking the extradition of a Chinese researcher from Switzerland for his part in a conspiracy to steal trade secrets from British pharmaceutical company GlaxoSmithKline.
EU invests €35m into AI cancer diagnostics
The European Commission has pledged €35 million to promote the development of analysis of health images for cancer diagnostics, based on artificial intelligence.
Europol busts major illicit steroid market
A worldwide operation has dismantled 17 organised crime groups involved in the trafficking of counterfeit doping materials and medicines, Europol has announced.
Hogan Lovells hires two new partners
Hogan Lovells has boosted its IP, media and technology practice with the addition of two life sciences specialists from McDermott Will & Emery.
